 |
|
|
| |
(HCV-TARGET) - Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
N Terrault, S Zeuzem, AM Di Bisceglie, JK Lim, PJ Pockros, LM Frazier, A Kuo, AS Lok, ML Shiffman, Z Ben Ari, T Stewart, MS Sulkowski, MW Fried, and DR Nelson for the HCV-TARGET Study Group
from Jules: of note, the authors report PPI use was associated with higher rate of failure; they also report high SVR/success with 8 weeks therapy, equal to 12 weeks:
|
| |
|
|
|
|
|
